Hemgenix Approved

A new treatment for adults with Haemophilia B has been given FDA approval.

Hemgenix, the first gene therapy for the genetic bleeding disorder, got the go-ahead in late November, providing new hope for sufferers.

Treatment with Hemgenix is given in a single dose. The product contains a viral vector carrying a gene for clotting Factor IX — a protein needed to produce blood clots to prevent bleeding.

The FDA granted approval of the drug to CSL Behring LLC. The application received Orphan, Priority Review and Breakthrough Therapy designations.

Back to the list